Processa Pharmaceuticals, Inc. (PCSA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 17, 2025, by Processa Pharmaceuticals, Inc., a Delaware corporation. The filing details the entry into a Material Definitive Agreement regarding a best efforts registered public offering of equity securities. The offering closed on June 18, 2025.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $6.3 million (excluding potential proceeds from warrant exercises).
- Securities Issued:
- 14,310,000 shares of Common Stock.
- Pre-Funded Warrants to purchase up to 13,690,000 shares.
- Common Warrants to purchase up to 28,000,000 shares.
- Pricing: Common Stock and accompanying Common Warrant sold at a combined price of $0.25 per unit. Pre-Funded Warrants and accompanying Common Warrants sold at a combined price of $0.2499 per unit.
- Transaction Costs:
- Placement Agent Cash Fee: 7.0% of gross proceeds.
- Non-accountable expense allowance: Up to $50,000.
- Legal fee reimbursement: Up to $100,000.
- Clearing expenses: $15,950.
- Placement Agent Warrants: 1,120,000 warrants issued at an exercise price of $0.3125.
Material Changes and Use of Proceeds
The filing does not provide comparative financial metrics (revenue, profit, cash flow) for the current period versus prior periods as this is a transactional filing rather than a periodic financial report. The primary material change is the increase in share count and dilution resulting from the issuance of approximately 28 million shares of common stock (direct and via pre-funded warrants) and 28 million common warrants.
The Company anticipates using the net proceeds to:
- Continue the Phase 2 clinical trial of NGC-Cap.
- Provide working capital and other general corporate purposes.
Guidance, Outlook, and Restrictions
Lock-Up Provisions: The Securities Purchase Agreement includes a 60-day standstill period during which the Company cannot issue additional common stock or equivalents. Additionally, the Company is restricted from engaging in "at-the-market" or continuous equity offerings for six months post-closing, with an exception for equity lines of credit or at-the-market offerings involving the Placement Agent after the 90-day anniversary.
Warrant Terms: Common Warrants have an exercise price of $0.25, are immediately exercisable, and expire five years after issuance. Pre-Funded Warrants have an exercise price of $0.0001 and are immediately exercisable.
Risks and Contingencies: The filing notes that the summary of terms is qualified by the full agreements attached as exhibits. No specific new risks or contingencies were disclosed beyond the standard dilution and market risks associated with equity offerings.
Key Facts for Investor Verification
- Verify the exact net proceeds after deducting the 7% placement fee, legal reimbursements, and other expenses.
- Confirm the current cash position and runway extension provided by the $6.3 million gross proceeds.
- Review the specific terms of the Phase 2 clinical trial for NGC-Cap to assess the likelihood of successful completion with the new funding.
- Monitor the impact of the 28 million new shares and 28 million warrants on earnings per share and voting control.
- Check for any subsequent filings regarding the exercise of Pre-Funded Warrants, which would further increase the share count.